We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Sep 2020 - 09 Sep 2020
Virtual Venue

Genetic Biomarkers Associated with Autism Spectrum Disorders Identified

By LabMedica International staff writers
Posted on 17 Dec 2019
Print article
Image: The Affymetrix CytoScan HD microarray suite provides the broadest coverage and highest performance for detecting chromosomal aberrations (Photo courtesy of Thermo Fisher).
Image: The Affymetrix CytoScan HD microarray suite provides the broadest coverage and highest performance for detecting chromosomal aberrations (Photo courtesy of Thermo Fisher).
Autism spectrum disorder (ASD) refers to a group of neurodevelopmental conditions resulting in challenges related to communication, social understanding and behavior. Studies show families who have a child with ASD have a 6.9% to 19.5% chance of another child having ASD and a 30% to 40% chance of another child having atypical development.

One of the key priorities of interventions for autism spectrum disorder (ASD) is starting early, with some evidence showing infants as young as seven months old could benefit. Yet, most children in North America are not diagnosed with ASD until they're over four years of age. Identification of genetic biomarkers associated with ASDs could improve recurrence prediction for families with a child with ASD.

A group of scientists collaborating with the Hospital for Sick Children (Toronto, ON, Canada) enrolled in a study, participants from 253 families enrolled (134 from USA sites and 119 from Canada). A total of 253 probands, 322 siblings (including 288 infant siblings), and 447 parents (242 mothers; 205 fathers) constituted the final cohort and were analyzed. All families had at least one child (i.e., the proband) diagnosed with ASD.

For microarray analysis, biological samples were obtained from 251 probands, 321 siblings and 444 parents (241 mothers; 203 fathers) at their respective recruiting sites (total samples = 1,016). Genomic DNA used for genotyping on microarray was extracted from whole blood (86.0%; 874/1,016 samples), saliva (0.4%; 4/1,016), lymphoblastoid cell lines (10.4%; 106/1,016), or source undocumented (3.1%; 32/1,016). Genomic DNA samples were processed on the high-density CytoScan HD microarray platform (Affymetrix, Santa Clara, CA, USA).

The team reported that the clinical microarray findings for 253 longitudinally phenotyped ASD families, encompassing 288 infant siblings showed that by age 3, 103 siblings (35.8%) were diagnosed with ASD and 54 (18.8%) were developing atypically. Thirteen siblings have copy number variants (CNVs) involving ASD-relevant genes: six with ASD, five atypically developing, and two typically developing. Within these families, an ASD-related CNV in a sibling has a positive predictive value (PPV) for ASD or atypical development of 0.83. The team has confirmed similar findings in a separate group of 2,110 families having one child with, and a second child without ASD.

Lonnie Zwaigenbaum, MD, FRCP (C), a Professor of Pediatrics and a senior study author, said, “These findings add to a growing body of evidence that biomarkers might be helpful in identifying pre-symptomatic infants who are likely to develop ASD or other developmental challenges.” The study was published on December 5, 2019 in the journal Nature Communication.

Related Links:
Hospital for Sick Children
Affymetrix



Print article

Channels

Industry News

view channel
Image: ChemWell RPR Analyzer (Photo courtesy of Awareness Technology, Inc.)

Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years

Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.